Scilex Holding Company (SCLXW)
US — Healthcare Sector
Peers:
Automate Your Wheel Strategy on SCLXW
With Tiblio's Option Bot, you can configure your own wheel strategy including SCLXW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SCLXW
- Rev/Share 4.3848
- Book/Share -18.2866
- PB -0.3812
- Debt/Equity -0.1963
- CurrentRatio 0.1041
- ROIC 0.5864
- MktCap 48452791.0
- FreeCF/Share 1.3415
- PFCF 3.123
- PE -1.0818
- Debt/Assets 0.5256
- DivYield 0
- ROE 0.359
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About Scilex Holding Company (SCLXW)
- IPO Date
- Website https://www.scilexholding.com
- Industry Drug Manufacturers - General
- CEO Mr. Jaisim Shah
- Employees 115
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company's principal product includes ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102 or SEMDEXA, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase 3 clinical trial to treat lumbosacral radicular pain; SP-103 for the treatment of low back pain, which is in Phase 2 clinical trails; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia that is in Phase 1 clinical trials. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.